Michael Barbella, Managing Editor04.09.22
Partnerships, purchases (past and present), and product permission pumped up MPO page views this past week.
Website visitors gravitated to Integer Holding Corporation's purchase of Aran Biomedical and the finalization of BD's Diabetes Business spinoff. The Integer's $131 million bid for Aran Biomedical Holdings Teoranta includes operating subsidiaries Aran Biomedical and Proxy Biomedical (collectively, “Aran”). Aran develops proprietary medical textiles, biomaterial coverings and coatings, and metal/polymer braiding. Integer executives said the deal increases the Galway, Ireland, company's portfolio for complex delivery and therapeutic devices for structural heart, neurovascular, peripheral vascular, endovascular, and general surgery.
With its spinoff complete, Becton Dickinson and Company has created one of the world's largest pure-play diabetes management firms—a.k.a., embecta. By spinning off its Diabetes Business, BD’s hopes to create two independent companies with attractive long-term shareholder value (BD retains no ownership in the new firm). embecta aims to build on its foundation as a leading maker of diabetes injection technology.
GE Healthcare single-handedly drove traffic as well over the last seven days by winning FDA approval for an anethesia delivery system and partnering with Elekta. The FDA granted the company PMA approval of its End-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 anesthesia delivery system. The technology was initially released in Europe in 2010 and is currently used in more than 100 countries. According to the company, Et Control software can help lower greenhouse gas emissions by 44 percent and increases accuracy in maintaining target oxygen and anesthetic agent concentrations. Keystrokes can be reduced by half and potential OR cost savings of 27 percent can be achieved through lower anesthetic agent spend and minimized waste.
GE Healthcare's non-exclusive commercial collaboration with Elekta focuses on radiation oncology. The two companies will offer hospitals an imaging and treatment technologies for cancer patients needing radiation therapy.
Website visitors gravitated to Integer Holding Corporation's purchase of Aran Biomedical and the finalization of BD's Diabetes Business spinoff. The Integer's $131 million bid for Aran Biomedical Holdings Teoranta includes operating subsidiaries Aran Biomedical and Proxy Biomedical (collectively, “Aran”). Aran develops proprietary medical textiles, biomaterial coverings and coatings, and metal/polymer braiding. Integer executives said the deal increases the Galway, Ireland, company's portfolio for complex delivery and therapeutic devices for structural heart, neurovascular, peripheral vascular, endovascular, and general surgery.
With its spinoff complete, Becton Dickinson and Company has created one of the world's largest pure-play diabetes management firms—a.k.a., embecta. By spinning off its Diabetes Business, BD’s hopes to create two independent companies with attractive long-term shareholder value (BD retains no ownership in the new firm). embecta aims to build on its foundation as a leading maker of diabetes injection technology.
GE Healthcare single-handedly drove traffic as well over the last seven days by winning FDA approval for an anethesia delivery system and partnering with Elekta. The FDA granted the company PMA approval of its End-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 anesthesia delivery system. The technology was initially released in Europe in 2010 and is currently used in more than 100 countries. According to the company, Et Control software can help lower greenhouse gas emissions by 44 percent and increases accuracy in maintaining target oxygen and anesthetic agent concentrations. Keystrokes can be reduced by half and potential OR cost savings of 27 percent can be achieved through lower anesthetic agent spend and minimized waste.
GE Healthcare's non-exclusive commercial collaboration with Elekta focuses on radiation oncology. The two companies will offer hospitals an imaging and treatment technologies for cancer patients needing radiation therapy.